Mostrando 5 resultados de: 5
Filtros aplicados
Publisher
Cancer Biology and Therapy(2)
Cancer Biotherapy and Radiopharmaceuticals(1)
Journal of Immunotherapy(1)
Seminars in Oncology(1)
Origen
scopus(5)
Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile
ArticleAbstract: Nimotuzumab is an EGFR-targeting antibody that has demonstrated encouraging clinical results in thePalabras claves:Affinity, Avidity, Cancer immunotherapy, eGFR, monoclonal antibodies, nimotuzumab, Tumor targetingAutores:Fernandez L.E., Garrido G., Gracia E., Iznaga N., Kerbel R.S., Pérez R., Rabasa A., Tania Crombet, Tikhomirov I.A., Yang E.Fuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopusNimotuzumab: beyond the EGFR signaling cascade inhibition
ReviewAbstract: One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activatesPalabras claves:antibody-dependent cell mediated cytotoxicity (ADCC), eGFR, HLA class I molecules, monoclonal antibodies, Natural killer cells, T cellsAutores:Chao L., Iznaga N., Lavastida A., Mazorra Z., Ramos M., Sanchez B., Tania CrombetFuentes:scopusPharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer
ArticleAbstract: Epidermal growth factor receptor (EGFR) overexpression has been detected in many tumors of epitheliaPalabras claves:Epidermal growth factor receptor, Monoclonal antibody, Phase I clinical trialAutores:Catala M., Iznaga N., Lage Davila A., Neninger Vinageras E., Perera A., Pérez R., Solano M., Tania Crombet, Torres F., Torres L., Torres O.Fuentes:scopusPhase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor
ArticleAbstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)Palabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitorsAutores:Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.Fuentes:scopus